Teva shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $10 to $14.
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries' stock (TEVA) has seen an increase in its trading price following an upgrade from 'Hold' to 'Buy' by Jefferies, which also raised its price target for the stock from $10 to $14.
January 23, 2024 | 6:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies upgraded Teva Pharmaceutical Industries' stock from 'Hold' to 'Buy' and increased the price target from $10 to $14, indicating a positive outlook on the company's future performance.
The upgrade by Jefferies to a 'Buy' rating, along with a significant raise in the price target, suggests a strong conviction in Teva's potential for growth and profitability. This is likely to instill confidence in investors and could lead to a short-term increase in the stock price as the market reacts to the positive analyst recommendation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100